These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 3048929)

  • 1. The role of pyrazinamide in tuberculosis chemotherapy.
    Steele MA; Des Prez RM
    Chest; 1988 Oct; 94(4):845-50. PubMed ID: 3048929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effectiveness and problems of PZA-containing 6-month regimen for the treatment of new pulmonary tuberculosis patients].
    Wada M
    Kekkaku; 2001 Jan; 76(1):33-43. PubMed ID: 11211781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Controlled trial of 2, 4, and 6 months of pyrazinamide in 6-month, three-times-weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin, and pyrazinamide. Results at 30 months. Hong Kong Chest Service/British Medical Research Council.
    Am Rev Respir Dis; 1991 Apr; 143(4 Pt 1):700-6. PubMed ID: 1901199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of a daily combined preparation of isoniazid, rifampin, and pyrazinamide in a controlled trial of three 6-month regimens for smear-positive pulmonary tuberculosis. Singapore Tuberculosis Service/British Medical Research Council.
    Am Rev Respir Dis; 1991 Apr; 143(4 Pt 1):707-12. PubMed ID: 1901200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pyrazinamide and rifampin vs isoniazid for the treatment of latent tuberculosis: improved completion rates but more hepatotoxicity.
    McNeill L; Allen M; Estrada C; Cook P
    Chest; 2003 Jan; 123(1):102-6. PubMed ID: 12527609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tolerance of pyrazinamide in short course chemotherapy for pulmonary tuberculosis in children.
    Sánchez-Albisua I; Vidal ML; Joya-Verde G; del Castillo F; de José MI; García-Hortelano J
    Pediatr Infect Dis J; 1997 Aug; 16(8):760-3. PubMed ID: 9271037
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acceptability, compliance, and adverse reactions when isoniazid, rifampin, and pyrazinamide are given as a combined formulation or separately during three-times-weekly antituberculosis chemotherapy.
    Hong Kong Chest Service/British Medical Research Council
    Am Rev Respir Dis; 1989 Dec; 140(6):1618-22. PubMed ID: 2604291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lung Tissue Concentrations of Pyrazinamide among Patients with Drug-Resistant Pulmonary Tuberculosis.
    Kempker RR; Heinrichs MT; Nikolaishvili K; Sabulua I; Bablishvili N; Gogishvili S; Avaliani Z; Tukvadze N; Little B; Bernheim A; Read TD; Guarner J; Derendorf H; Peloquin CA; Blumberg HM; Vashakidze S
    Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28373198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of isoniazid-resistant tuberculosis with isoniazid, rifampin, ethambutol, and pyrazinamide for 6 months.
    Nolan CM; Goldberg SV
    Int J Tuberc Lung Dis; 2002 Nov; 6(11):952-8. PubMed ID: 12475140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bioavailability of isoniazid, rifampicin and pyrazinamide (in free combination or fixed-triple formulation) in intermittent antituberculous chemotherapy.
    Acocella G; Luisetti M; Grassi GG; Peona V; Pozzi E; Grassi C
    Monaldi Arch Chest Dis; 1993; 48(3):205-9. PubMed ID: 8369784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Controlled trial of 6-month and 8-month regimens in the treatment of pulmonary tuberculosis. First report.
    Am Rev Respir Dis; 1978 Aug; 118(2):219-28. PubMed ID: 100029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Hepatic functional changes induced by the combined use of isoniazid, pyrazinamide and rifampicin in the treatment of pulmonary tuberculosis].
    de Souza AF; de Oliveira e Silva A; Baldi J; de Souza TN; Rizzo PM
    Arq Gastroenterol; 1996; 33(4):194-200. PubMed ID: 9302332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety of 3 different reintroduction regimens of antituberculosis drugs after development of antituberculosis treatment-induced hepatotoxicity.
    Sharma SK; Singla R; Sarda P; Mohan A; Makharia G; Jayaswal A; Sreenivas V; Singh S
    Clin Infect Dis; 2010 Mar; 50(6):833-9. PubMed ID: 20156055
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis.
    Yee D; Valiquette C; Pelletier M; Parisien I; Rocher I; Menzies D
    Am J Respir Crit Care Med; 2003 Jun; 167(11):1472-7. PubMed ID: 12569078
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The effectiveness of pyrazinamide-containing six-month short course chemotherapy].
    Wada M
    Kekkaku; 2000 Nov; 75(11):665-73. PubMed ID: 11140090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low antituberculosis drug concentrations in patients with AIDS.
    Peloquin CA; Nitta AT; Burman WJ; Brudney KF; Miranda-Massari JR; McGuinness ME; Berning SE; Gerena GT
    Ann Pharmacother; 1996 Sep; 30(9):919-25. PubMed ID: 8876848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatotoxicity of rifampin-pyrazinamide and isoniazid preventive therapy and tuberculosis treatment.
    van Hest R; Baars H; Kik S; van Gerven P; Trompenaars MC; Kalisvaart N; Keizer S; Borgdorff M; Mensen M; Cobelens F
    Clin Infect Dis; 2004 Aug; 39(4):488-96. PubMed ID: 15356811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Controlled clinical trial of five short-course (4-month) chemotherapy regimens in pulmonary tuberculosis. Second report of the 4th study. East African/British Medical Research Councils Study.
    Am Rev Respir Dis; 1981 Feb; 123(2):165-70. PubMed ID: 7015933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of tuberculosis in patients with advanced human immunodeficiency virus infection.
    Small PM; Schecter GF; Goodman PC; Sande MA; Chaisson RE; Hopewell PC
    N Engl J Med; 1991 Jan; 324(5):289-94. PubMed ID: 1898769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of rifampin and pyrazinamide for the treatment of latent tuberculosis infection.
    Stout JE
    Expert Opin Drug Saf; 2004 May; 3(3):187-98. PubMed ID: 15155147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.